Milrinone Systematic (IUPAC) name 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile Clinical data AHFS/Drugs.com MedlinePlus Pregnancy cat. C(US) Legal status ℞ Prescription only Routes IV only Pharmacokinetic data Bioavailability 100% (as IV bolus, infusion) Protein binding 70 to 80% Metabolism Hepatic (12%) Half-life 2.3 hours (mean, in CHF) Excretion Urine (85% as unchanged drug) within 24 hours Identifiers CAS number ATC code C01 PubChem DrugBank ChemSpider UNII KEGG ChEBI ChEMBL Chemical data Formula C12H9N3O Mol. mass 211.219 g/mol SMILES & Physical data Density 1.344 g/cm³ Melt. point 315 °C (599 °F) Boiling point 449 °C (840 °F) (what is this?)
Milrinone (Primacor) is a phosphodiesterase 3 inhibitor. It potentiates the effect of cyclic adenosine monophosphate (cAMP).
It has positive inotropic, vasodilating and minimal chronotropic effects. It is used in the management of heart failure only when conventional treatment with vasodilators and diuretics has proven insufficient. This is due to the potentially fatal adverse effects of milrinone, including ventricular arrhythmias.
One negative side to the use of milrinone is the short half-life (1 to 2 hours). This can result in a prolonged weaning and possible adverse outcomes from stopping this medication rapidly.
Singh, B.; 1983, U.S. Patent 4,413,127.
Phosphodiesterase inhibitors PDE1MMPX • SCH-51866 • Vinpocetine PDE2BAY 60-7550 • EHNA PDE3 PDE4 PDE5 PDE6Zaprinast PDE7BRL-50481 PDE9BAY 73-6691 • SCH-51866 PDE10 Nonselective Cardiac stimulants excluding cardiac glycosides (C01C) Adrenergic and
Phosphodiesterase inhibitors (PDE3I) Other cardiac stimulants This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.